New research in the Journal of Clinical Oncology suggests that men on androgen deprivation therapy (ADT) are at higher risk for Alzheimer's disease. 

ADT is a common treatment for prostate cancer. Because androgens can fuel the growth of prostate cancer cells, the therapy aims to reduce androgen levels through surgery or regularly administered medications. 

The study was conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania and the Stanford School of Medicine. 

They analyzed electronic medical data from 16,888 men with prostate cancer. Overall, 14% underwent ADT. The men were followed for a median of 2.7 years. 

The researchers found that men on ADT had more Alzheimer's diagnoses during the follow-up period than those who did not undergo ADT.  Also, the risk of Alzheimer's increased with the length of time men were on ADT. 

The scientists were not certain why this association occurred. More research is needed. 

Please click here to learn more about this study. 

Have you checked out the Video Journal of Prosthetic Urology (VJPU) lately? Two new videos were recently added.  

The first, "Dorsal Phalloplasty: Minimizing Shortening upon Penile Prosthesis Implantation by Tucking-in the Peno-Pubic Junction" was produced by Prof. Osama Shaeer, MD, PhD and Prof. Kamal Shaeer, MD of Cairo University in Egypt. 

The second, "Transcorporal Artificial Urinary Sphincter placement in patients with prior Inflatable Penile Prosthesis utilizing a 6 ply Acellular Graft" comes from Melissa Mendez, MD and Aaron Lentz, MD of Duke University Medical Center in the United States. 

You can find all of the VJPU videos here.